Deutsche Bank AG Buys 75,994 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Deutsche Bank AG lifted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 53.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 217,723 shares of the company's stock after buying an additional 75,994 shares during the period. Deutsche Bank AG owned approximately 0.06% of Recursion Pharmaceuticals worth $1,472,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Farther Finance Advisors LLC raised its stake in shares of Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after buying an additional 1,353 shares in the last quarter. Summit Investment Advisors Inc. raised its stake in shares of Recursion Pharmaceuticals by 7.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company's stock worth $176,000 after buying an additional 1,875 shares in the last quarter. Daiwa Securities Group Inc. raised its position in shares of Recursion Pharmaceuticals by 28.3% during the fourth quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company's stock worth $69,000 after purchasing an additional 2,235 shares during the period. NewEdge Advisors LLC raised its position in shares of Recursion Pharmaceuticals by 43.7% during the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after purchasing an additional 2,387 shares during the period. Finally, Xponance Inc. raised its position in shares of Recursion Pharmaceuticals by 22.2% during the fourth quarter. Xponance Inc. now owns 19,163 shares of the company's stock worth $130,000 after purchasing an additional 3,480 shares during the period. Institutional investors own 89.06% of the company's stock.

Analysts Set New Price Targets

RXRX has been the topic of a number of recent analyst reports. Morgan Stanley cut their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Needham & Company LLC cut their target price on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Finally, Leerink Partners cut their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research report on Friday, February 28th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $7.60.

Recursion Pharmaceuticals Stock Up 3.1%

Shares of RXRX stock traded up $0.14 on Thursday, reaching $4.54. 9,784,968 shares of the company's stock traded hands, compared to its average volume of 22,597,967. Recursion Pharmaceuticals, Inc. has a 12-month low of $3.79 and a 12-month high of $12.36. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The company has a market capitalization of $1.84 billion, a P/E ratio of -2.96 and a beta of 0.99. The business's 50 day moving average price is $5.00 and its two-hundred day moving average price is $6.45.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. During the same quarter last year, the firm earned ($0.39) EPS. The business's revenue for the quarter was up 7.2% compared to the same quarter last year. On average, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.